Patient‐Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular‐Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two‐Year Results From an International Phase III Study
Authors' conclusion
Early and sustained PRO improvements were reported in this phase III, open-label trial of subcutaneous abatacept in patients with pJIA.
Study context
- Population
- Children with pJIA treated with subcutaneous abatacept
- Participants
- 173 vs 46
- Comparison
- 6- TO 17-YEAR-OLD vs 2- TO 5-YEAR-OLD
- 6- TO 17-YEAR-OLDn = 173
- 2- TO 5-YEAR-OLDn = 46
Methodological details24-month, international
- 24-month
- International
Primary result
As reported in the abstract
Median (Q1, Q3) change from baseline in Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) · months 4 and 24
| Group | Value | Month 4 | Month 24 |
|---|---|---|---|
| 6 to 17 years | median −0.3 (IQR −0.8–0.0) | −0.3 (−0.8, 0.0) | −0.5 (−1.0, −0.1) |
| 2 to 5 years | median −0.4 (IQR −0.8–0.0) | −0.4 (−0.8, 0.0) | −0.5 (−1.0--0.1) |
Value
6 to 17 yearsmedian −0.3 (IQR −0.8–0.0)
2 to 5 yearsmedian −0.4 (IQR −0.8–0.0)
Month 4
6 to 17 years−0.3 (−0.8, 0.0)
2 to 5 years−0.4 (−0.8, 0.0)
Month 24
6 to 17 years−0.5 (−1.0, −0.1)
2 to 5 years−0.5 (−1.0--0.1)
Further findings
Median pain score · month 1 and month 24
Month 1 6 to 17 years 32.3 mm · 2 to 5 years 25.7 mm
Month 24 (nadir) 6 to 17 years 6.0 mm · 2 to 5 years 2.0 mm
| Outcome | 6 to 17 years | 2 to 5 years |
|---|---|---|
| Median PaGA score · baseline and month 24 | ||
| Baseline (n = 172) | 47.8 | — not stated in the abstract |
| Month 24 (n = 107) | 6.3 | — not stated in the abstract |
| Baseline (n = 46) | — not stated in the abstract | 42.1 |
| Month 24 (n = 37) | — not stated in the abstract | 2.0 |
— not stated in the abstract
- Median pain score: value shown is month 1
- Median PaGA score: value shown is month 24
Median pain score · month 1 and month 24
- Median pain scores below cutoff threshold for clinically relevant pain (<35 mm) by month 1
ALQ components · month 4 to month 24
- In both cohorts, ALQ components improved from baseline to month 4 and were largely maintained to month 24
Clinical outcomes (JIA ACR50, clinically inactive disease, Juvenile Arthritis Disease Activity Score) · month 24
- Clinical outcomes improved through to month 24
Original publication
Patient‐Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular‐Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two‐Year Results From an International Phase III Study. Arthritis Care Res (Hoboken). Published 29 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →